Cizutamig

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 10:41:52 GMT 2025` Edited by `admin` on `Wed Apr 02 10:41:52 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	P5TLS56PWW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMB-06

Preferred Name

English

Cizutamig

Official Name

English

fused L-kappa-H-gamma1 heavy chain anti-TNFRSF17 and anti-CD3E humanized (1-663) [[L-kappa anti-TNFRSF17 humanized (1-214) [V-KAPPA (Homo sapiens IGKV1-39*01 (82.1%) -IGKJ2*02 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (1

Common Name

English

Immunoglobulin G1, bispecific, anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal EMB-06 ?-chain) fusion protein with immunoglobulin G1 anti-(human CD3 antigen ?-chain) (human-Mus musculus monoclonal E

Common Name

English

immunoglobulin [L-kappa-H-gamma1_[VH-G1(CH1-h)]_Lkappa] dimer, anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)],

Common Name

English

cizutamig [INN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C179632

Created by admin on Wed Apr 02 10:41:52 GMT 2025 , Edited by admin on Wed Apr 02 10:41:52 GMT 2025

PRIMARY

SMS_ID

300000056812

Created by admin on Wed Apr 02 10:41:52 GMT 2025 , Edited by admin on Wed Apr 02 10:41:52 GMT 2025

PRIMARY

INN

13166

Created by admin on Wed Apr 02 10:41:52 GMT 2025 , Edited by admin on Wed Apr 02 10:41:52 GMT 2025

PRIMARY

FDA UNII

P5TLS56PWW

Created by admin on Wed Apr 02 10:41:52 GMT 2025 , Edited by admin on Wed Apr 02 10:41:52 GMT 2025

PRIMARY

CAS

2919209-65-5

Created by admin on Wed Apr 02 10:41:52 GMT 2025 , Edited by admin on Wed Apr 02 10:41:52 GMT 2025

PRIMARY

From	To
6_139	6_199
6_23	6_94
5_139	5_199
5_23	5_94
4_148	4_204
4_22	4_96
2_214	4_224
1_214	3_224
2_436	6_219
1_436	5_219
2_583	2_641
3_148	3_204
3_22	3_96
2_477	2_537
2_360	2_416
2_236	2_310
2_134	2_194
2_23	2_88
1_583	1_641
1_477	1_537
1_445	2_445
1_442	2_442
1_360	1_416
1_236	1_310
1_134	1_194
1_23	1_88

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_513
N	2_513

Related Record Type Details


					PK6VHJAIBD

TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17

TARGET->LIGAND

Interaction Type:

PRECLINICAL

Amount:


					ZLW14X2D30

CD3

TARGET -> ACTIVATOR

Interaction Type:

PRECLINICAL

Amount:

Related Record Type Details


					P5TLS56PWW

Cizutamig

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_663] [2_663]	C-TERMINUS	K		LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL